Dr. Ajeet Sidana


Objective: Craving plays significant role in relapse in patients with alcohol dependence syndrome. Baclofen and topirmate are effective in
reduction of craving and maintenance of abstinence in various placebo controlled trials.
Method: It is a retrospective study of patients of alcohol dependence who were admitted in de-addiction ward from January- December 2013. Case
record files of patient who completed detoxification and were prescribed either baclofen or topiramate were taken out and analyzed after applying
coding plan.
Results: A total of 68 patients fulfilled the inclusion criteria, 40 in baclofen group and 28 in topiramte group. Mean age was 38 years in baclofen
group and 41 years in topiramate group. Majority of the patients in both the groups were married and employed. Majority of the patients in both the
groups had duration of alcohol dependence between 5-10 years. 32.5 % patients in baclofen group did not report craving at 3 months against 14.2%
in topiramte group and 47.5% patients in baclofen group remained abstinent at 3 months against 28.5% in topiramate group.
Conclusion: Both baclofen and topiramate are effective in reduction of craving and maintaining abstinence in patients with alcohol dependence
syndrome and baclofen fared better than topiramate.


Baclofen, Topiramate, Alcohol Dependence

Full Text:



McLellan AT, Lewis DC, O’Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA J Am Med Assoc 2000;284:1689–95.

Swift RM. Drug therapy for alcohol dependence. N Engl J Med 1999;340:1482–90.

Finney JW, Hahn AC, Moos RH. The effectiveness of inpatient and outpatient treatment for alcohol abuse: the need to focus on mediators and moderators of setting effects. Addict Abingdon Engl 1996;91:1773–1796; discussion 1803–1820.

Addolorato G, Caputo F, Capristo E, Colombo G, Gessa GL, Gasbarrini G. Ability of baclofen in reducing alcohol craving and intake: II--Preliminary clinical evidence. Alcohol ClinExp Res 2000;24:67–71.

Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 2003;361:1677–85.

Addolorato G, Caputo F, Capristo E, Domenicali M, Bernardi M, Janiri L, et al. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol AlcoholOxfOxfs 2002;37:504–8.

Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007;370:1915–22.

Rubio G, Martínez-Gras I, Manzanares J. Modulation of impulsivity by topiramate: implications for the treatment of alcohol dependence. J ClinPsychopharmacol 2009;29:584–9.

Rozatkar AR, Kapoor A, Sidana A, Chavan BS. Clinical experience of baclofen in alcohol dependence: A chart review.Ind Psychiatry J 2016;25:11-6.

Sidana A, Rai S, Chavan BS. Alcohol Dependence Syndrome. One year outcome study. Delhi Psychiatry J 2007; 10:1: 53-57.

Neto D, Lambaz R, Tavares JE. Compliance with aftercare treatment, including disulfiram, and effect on outcome in alcohol-dependent patients.Alcohol Alcohol. 2007;42(6):604-9.

Terra MB, Barros HM, Stein AT, Figueira I, Athayde LD, Ott DR, de AzambujaRde C, da Silveira DX. Predictors of relapse in 300 Brazilian alcoholic patients: a 6-month follow-up study.Subst Use Misuse 2008;43(3-4):403-11.


  • There are currently no refbacks.